Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11156MR)

This product GTTS-WQ11156MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454
UniProt ID P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11156MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10334MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ4186MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ14622MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ4715MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ4280MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ11094MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ14455MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ4066MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW